Dr Janet Scott

Research Interests

Dr. Scott is a Clinical Lecturer in Pharmacology and Infectious Disease at the University of Liverpool. Her main research interests are optimizing the doses of therapeutics using pharmacokinetic and pharmacodynamic models in particular anti-Ebola and anti-Schistosome therapeutics. She trained in Parasitology at the University of Glasgow and holds a PhD in the cellular immuno-epidemiology of Schistosomiasis also from the University of Glasgow with research in The Gambia and Zimbabwe. Between 1997 and 2002 she continued her interest in the schistosome immunology in the North of Senegal, based in the Institute of Tropical Medicine, Antwerp. In 2002 she moved to Oxford to read Medicine. In 2006 she joined the Jenner Institute, Oxford to study a Tuberculosis candidate vaccine and prepare trial sites in Kenya for an HIV vaccine study. During the Ebola 2014-16 epidemic she was the clinical lead for the Brincidofovir Trial (Monrovia, Liberia), and Convalescent Plasma (Freetown, Sierra Leone) and is currently the Principal Investigator (University of Liverpool) for the Characterizing Post Ebola Syndrome, Sierra Leone which supports clinical care for Ebola Survivors and provides a research platform for collaborative research into Post Ebola Syndrome.

Characterizing Post Ebola Syndrome, Sierra Leone is a collaborative project with Military Hospital 34, Freetown, Sierra Leone and Dr. Calum Semple. The project aims to provide clinical care for survivors of Ebola Virus Disease, characterise post Ebola syndrome and facilitate collaborative research. Further media links to this project can be found on the University of Liverpool's News Website, including the most collaborative research venture with St. Paul's Eye Department, Liverpool Royal Hospital., which produced the widely reported paper Novel Retinal Lesion in Ebola Survivors, Sierra Leone, 2016.

Research collaborations

Dr. Calum Semple, University of Liverpool

Characterizing Post Ebola Syndrome, Sierra Leone

Convalescent Plasma for the treatment of Early Ebola Virus Disease (Ebola_CP)

Brig. General Prof. Foday Sahr, Surgeon General, Sierra Leone

Military Hospital 34, Freetown, Sierra Leone

Characterizing Post Ebola Syndrome Sierra Leone

Convalescent Plasma for the treatment of Early Ebola Virus Disease (Ebola_CP)

Personal Distinctions

Clinical Lecturer Prize (Prize, University of Liverpool 2017)

Ebola Medal (UK Government 2016)

UK-Sierra Leone Health Partners Annual Conference 2016 (Invitation to Speak, All Party Parliamentary Group on Global Health 2016)

Clinical Fellowship in Biomedical Science (Competitive Fellowship, University of Liverpool and Wellcome Trust 2014)

Prize Scholarship for HIV Vaccine Research (Prize, Bill and Melinda Gates Foundation 2007)

Medical Elective Prize (Prize, Wellcome Trust 2006)

Prize in Psychiatry (Prize, University of Oxford 2005)

Graham Kerr Prize in Parasitology (Prize, University of Glasgow 1993)

Press Media

Image of three children in Sierra Leone walking by a red wall with the word Ebola

Those who are fortunate enough to survive infection with the Ebola virus could still face multiple health problems. New research says 80 percent of Ebola survivors suffer disabilities one year after being discharged from the hospital. Voice of American Joe De Capua reports.


Can the Ebola Virus live on undetected, Friday 9th October 2015 BBC World Service?


Ebola epidemic over but flare-ups likely. 14th January 2016



MRC, University of Glasgow and CVR logos